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Evidence is accumulating that endogenous nitric oxide (NO) is involved in the pathophysiology of asthma. NO is formed by NO synthase (NOS) using L-arginine as a substrate. It has been shown that the level of NO in exhaled air is increased in subjects with asthma, and that it varies with disease severity. 1 However, the functional role of NO in the pathophysiology of asthma is still unclear.
Recent studies on the modulation of endogenous NO production have revealed protective features of NO during episodes of airways obstruction. Increased airway hyperresponsiveness to non-sensitising stimuli has been observed following inhalation of NOS inhibitors in mildly asthmatic subjects, 2 whereas this could not be found in patients with more severe asthma. 3 Based on these findings, it can be postulated that airways obstruction in asthma is associated with an endogenous NO deficiency due to limited availability of NOS substrate. We therefore examined the protective eVect of oral supplementation of the natural substrate of NOS (L-arginine) on relatively mild and more severe histamine induced airways obstruction in patients with asthma.
Methods
The study subjects comprised 14 nonsmoking, atopic, asthmatic patients using inhaled short acting 2 agonists on demand only. They had episodic chest symptoms, their baseline forced expiratory volume in one second (FEV 1 ) ranged from 82% to 115% predicted, and all were hyperresponsive to inhaled histamine (provocative concentration causing a fall in FEV 1 of 20% (PC 20 ) 0.04-6.5 mg/ml). They were asked to refrain from using bronchodilators for at least eight hours before testing.
In a double blind, randomised, crossover study the patients received pretreatment with oral L-arginine or placebo on two separate days separated by an interval of 1-2 weeks. Exhaled NO, FEV 1 , blood pressure, and heart rate were measured before (baseline) and at 30, 60, and 90 minutes following pretreatment, after which a histamine challenge was performed. Gelatin capsules containing L-arginine (50 mg/kg body weight; Bufa, Uitgeest, The Netherlands) or placebo (cellulose) were given 90 minutes before standardised histamine challenges using the two minute tidal breathing method. To examine the eVects of L-arginine on mild as well as severe degrees of airways obstruction, the challenge test was continued until a 50% fall in FEV 1 from baseline was obtained or when the highest dose was reached. The response was expressed as PC 20 as a measure of airways sensitivity, whilst the dose-response slope was calculated (maximal % fall in FEV 1 / maximal dose of histamine (µmol)) as a measure of airways reactivity. rado, USA) during a vital capacity manoeuvre with a standardised expiratory flow of 0.05 times baseline forced vital capacity per second (0.05 × FVC/s). The subjects inspired "NOfree" air (<2 ppb) during the measurements with their noses clipped. Mean exhaled NO was determined at the plateau and expressed as parts per billion (ppb).
All results were analysed by MANOVA and Student's paired and unpaired t tests. p values of <0.05 were considered statistically significant.
The study was approved by the medical ethics committee of the Leiden University Medical Center and all participants gave informed consent.
Results
All subjects completed the study. The data are presented in table 1. Baseline FEV 1 and exhaled NO did not diVer between the two study days (mean diVerence 3.8% predicted (95% CI -0.9 to 8.5) and 2.5 ppb (95% CI -2.4 to 7.4), respectively; p>0.2). There was a slight but significant improvement in FEV 1 following placebo (p = 0.03) but no significant change in FEV 1 occurred following pretreatment with L-arginine (p = 0.45; table 1). However, the pre-histamine baseline FEV 1 was not significantly diVerent between the two study days (mean diVerence -1.3% predicted (95% CI -4.0 to 1.4), p = 0.3). There was no significant change in exhaled NO levels after L-arginine or placebo (p>0.1; table 1) nor were blood pressure and heart rate significantly aVected (p>0.4).
Supplementation with L-arginine did not significantly aVect airway sensitivity to histamine, determined by PC 20 , compared with placebo (mean change in doubling dose: 0.18 (95% CI -0.36 to 0.71, p = 0.5). However, there was a slight but significant reduction in airway reactivity as determined by the doseresponse slope following pretreatment with L-arginine compared with placebo (mean change 0.7 (95% CI 0.6 to -0.9), p = 0.016).
Discussion
These results show that oral L-arginine does not aVect airway hyperresponsiveness to inhaled histamine in patients with asthma, although a slight reduction in airway reactivity (as indicated by the dose-response slope) was seen. These findings suggest only marginal limitation of NOS substrate in asthmatic subjects in vivo and therefore argue against a clinically relevant deficiency of endogenous NO in asthma. This is the first study of the eVects of L-arginine supplementation on airway hyperresponsiveness in patients with asthma. Previous animal studies have demonstrated the ability of L-arginine to reverse the enhanced bronchoconstriction to non-sensitising stimuli following inhibition of NO synthesis 5 and to reduce contractility to histamine in vitro. 6 In addition, they provided indirect evidence for an association between endogenous NO deficiency and the increase in airway sensitivity and reactivity following either respiratory virus infection 7 or allergen exposure in guinea pigs. 8 Our results do not confirm these findings, although a slight improvement in airway reactivity occurred following supplementation with oral L-arginine.
It is unlikely that our results can be explained by measurement errors since they were obtained using validated methodology for challenge testing 4 and measurement of exhaled NO. The dose and timing of L-arginine pretreatment were based on a previous report which showed increased levels in exhaled NO two hours after ingestion of 50 mg/kg L-arginine in asthmatic subjects. 9 In this study, however, we were not able to detect an increase in exhaled NO. Since our patients did not have an L-arginine deficient or weighted diet, we cannot exclude the possibility that these subjects had little or no NOS substrate limitation. Finally, since high concentrations of L-arginine have been shown to act as a non-competitive antagonist of the contractile response to histamine in vitro, 6 we cannot exclude the contribution of the anti-histamine eVects of L-arginine to the present findings.
Besides having immunomodulatory and cytotoxic properties, NO is known to exert protective eVects within the airways. 2 This "relaxant" eVect is likely to be derived from constitutive NOS activity (cNOS), of which neuronal NOS (nNOS) in inhibitory non-adrenergic noncholinergic (iNANC) nerves seems to predominate. It has been suggested that a deficiency of endogenous "relaxant" NO is one of the underlying mechanisms for increased responses to bronchoconstrictor stimuli in asthma. 3 This may be explained either by a reduction in NOS activity and/or reduced local availability of the NOS substrate. Asthma has been associated with increased exhaled NO levels, 1 of which the major part seems to derive from local inducible NOS (iNOS) activity. The relatively high NO levels produced by iNOS may subsequently attenuate cNOS activity, 10 thereby potentially reducing its relaxant effects.
Since L-arginine is metabolised not only by NOS, but also by arginase, increased arginase levels and/or activity may limit L-arginine availability. Indeed, both NOS and arginase activity may be increased during inflammation. More importantly, at reduced L-arginine levels, argi- nase activity is favoured over NO synthesis. 11 However, at present there is no evidence of increased arginase levels and/or activity in asthma. Finally, Chakder and colleagues reported that continuous iNANC activation in smooth muscle strips caused significant decreases in levels of L-arginine. 12 It can be speculated that in asthma the iNANC system may be perpetually activated, thereby exhausting its own bronchodilator features. It remains to be elucidated whether these in vitro findings can be extrapolated to the human situation.
